A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients.
Front Oncol
; 13: 1182725, 2023.
Article
in En
| MEDLINE
| ID: mdl-37313470
Full text:
1
Database:
MEDLINE
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Language:
En
Year:
2023
Type:
Article